Affiliation:
1. Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Abstract
Abstract
Background
We hypothesized that elevations of plasma Oncostatin M (OSM) would be associated with infliximab nonresponse.
Methods
Plasma OSM was measured in Crohn disease patients pre-infliximab with biochemical response (>50% reduction in fecal calprotectin) as the primary outcome.
Results
The median OSM in biochemical responders was 86 (69–148) pg/mL compared with 166 (74–1766) pg/mL in nonresponders (P = 0.03). Plasma OSM > 143.5 pg/mL was 71% sensitive and 78% specific for biochemical nonresponse (area under the curve 0.71). Early biochemical nonremission was also associated with an elevated neutrophil CD64 expression (odds ratio 8.9, P = 0.011).
Conclusions
Elevated preinfliximab plasma OSM and nCD64 surface expression were both associated with poor biochemical outcomes.
Funder
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
Cincinnati Children’s Research Foundation Trustee Award Program
Digestive Disease Research Core Center in Cincinnati
Crohn’s and Colitis Foundation PRO-KIIDS Award
Janssen
Publisher
Oxford University Press (OUP)
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献